Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Sanofi 3Q11

Earnings down due to generic competition

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi 3Q11

2Q Revenues: €8.8 billion (+5%)

2Q Earnings: €2.4 billion (-3%)

YTD Revenues: €24.9 billion (+1%)

YTD Earnings: €4.3 billion (-15%)

Comments: Pharmaceutical sales were €6.9 billion in the quarter (+10%). Lantus sales were up 14% to €968.0 million. Eloxatin sales were €310.0 million, up 179%. Taxotere sales were down 65% to €186.0 million and Lovenox sales were down 16% to €494.0 million, due to generic competition. Genzyme sales were €768.0 million, up 7% and accounted for 69% of total sales. Diabetes sales increased 12% driven by a strong performance in the U.S. and Emerging Markets, where Lantus sales growth was 15% and 23%, respectively. Vaccines grew 17% due to demand for seasonal flu vaccines in the U.S. Consumer Health Care sales were €665.0 million (+20%), driven by Allegra OTC launch in the U.S.  Unfavorable currency exchange impacted results by 5%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters